Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IONIS PHARMACEUTICALS INC (IONS)

Ionis cuts TRYNGOLZA 2026 sales guidance to about $50 million; Q3 revenue rises

Mixed Impact 4 of 5 guidance

Ionis reported third quarter 2026 revenue of $243 million, up from $157 million a year earlier, and a narrower net loss of $110 million, compared with $129 million. The company lowered its 2026 TRYNGOLZA product sales guidance to about $50 million, from $100-110 million, citing a more gradual launch, and reaffirmed its total revenue, operating loss and cash guidance.

Key points

  • Third quarter 2026 total revenue was $243 million versus $157 million in the same period of 2025.
  • Basic and diluted net loss per share was $0.66, compared with $0.80 a year earlier.
  • 2026 TRYNGOLZA product sales guidance was lowered from $100-110 million to about $50 million.
  • Total revenue guidance of $875-900 million and DAWNZERA product sales guidance of $110-120 million were unchanged.

The filing

CompanyIONIS PHARMACEUTICALS INC (IONS)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:00 AM ET
Accession number0001140361-26-042598

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:10 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.